Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tolerability of HS-20004 in Type 2 Diabetes
NCT02750007Phase 1Unknown
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Dec 2015
- Primary completion
- Jan 2017
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of noiiglutide in type 2 diabetes mellitus (T2DM), sponsored by Hansoh Pharmaceutical Group. Primary endpoint: Number of Treatment Emergent Adverse Events at 8 weeks. Status: unknown.
02
Drugs
noiiglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02750007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02750007.